Recombinant human erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells

Joint Authors

How, Chee Wun
Shuja al-Din, Harith Y.
al-Hajj, Naji A.
Rasidi, Abd Allah
Bin Alitheen, Noorjahan
Abd al-Qadir, Arifah
Rahman, Heshu Sulayman
al-Shuwayh, Hussah Abd Allah

Source

Saudi Journal of Biological Sciences

Issue

Vol. 28, Issue 9 (30 Sep. 2021), pp.5214-5220, 7 p.

Publisher

Saudi Biological Society

Publication Date

2021-09-30

Country of Publication

Saudi Arabia

No. of Pages

7

Main Subjects

Biology

Abstract EN

Erythropoietin (EPO) is widely used to treat anemia in patients undergoing chemotherapy for cancers.

The main objective of this study was to investigate the effect of rHuEPO on the response of spheroid breast cancer, MCF-7, cells to tamoxifen treatment.

The MCF-7 spheroids were treated with 10 mg/mL tamoxifen in combination with either 0, 10, 100 or 200 IU/mL rHuEPO for 24, 48 or 72 h.

The viability of the MCF-7 cells was determined using the annexin-V, cell cycle, caspases activation and acridine orange/propidium iodide staining.

rHuEPO-tamoxifen combination significantly (p greater than 0.05) increased the number of spheroid MCF-7 cells entering early apoptotic phase after 12 h and late apoptotic phase after 24 h of treatment; primarily the result of the antiproliferative effect tamoxifen.

Tamoxifen alone significantly (p < 0.05) increased the caspase-3 and -9 activities in the spheroid MCF-7 cells by 200 to 550% of the control.

Combination rHuEPO and tamoxifen produced much lesser effect on the caspase-8 activity.

The rHuEPO in the combination treatment had concentration-dependently caused decrease in the caspase activities.

rHuEPO-tamoxifen combination markedly increased MCF-7 cells entering the SubG0/G1 phase of the cell cycle by more than 500% of the control, while decreasing those entering the G2 + M and S phases by 50%.

After 72 h, the combination treatment produced greater (p < 0.05) change in the SubG0/G1 phase than tamoxifen treatment alone.

Morphologically, spheroid MCF-7 cells subjected to combination rHuEPO-tamoxifen treatment showed nuclear condensation and margination, cytoplasmic blebbing, necrosis, and early and late apoptosis.

Thus, the study showed that rHuEPO-tamoxifen combination induced apoptosis in the spheroid MCF-7 cells.

The apoptotic effect of the rHuEPO-tamoxifen combination treatment on the MCF-7 cells was greater than that produced by tamoxifen alone.

The rHuEPO-tamoxifen treatment enhanced the caspase-independent apoptotic effects of tamoxifen on the spheroid MCF-7 cells.

American Psychological Association (APA)

Shuja al-Din, Harith Y.& al-Hajj, Naji A.& Rasidi, Abd Allah& Bin Alitheen, Noorjahan& Abd al-Qadir, Arifah& How, Chee Wun…[et al.]. 2021. Recombinant human erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells. Saudi Journal of Biological Sciences،Vol. 28, no. 9, pp.5214-5220.
https://search.emarefa.net/detail/BIM-1410632

Modern Language Association (MLA)

Shuja al-Din, Harith Y.…[et al.]. Recombinant human erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells. Saudi Journal of Biological Sciences Vol. 28, no. 9 (2021), pp.5214-5220.
https://search.emarefa.net/detail/BIM-1410632

American Medical Association (AMA)

Shuja al-Din, Harith Y.& al-Hajj, Naji A.& Rasidi, Abd Allah& Bin Alitheen, Noorjahan& Abd al-Qadir, Arifah& How, Chee Wun…[et al.]. Recombinant human erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells. Saudi Journal of Biological Sciences. 2021. Vol. 28, no. 9, pp.5214-5220.
https://search.emarefa.net/detail/BIM-1410632

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references : p. 5220

Record ID

BIM-1410632